Paolo Tarantino shared on X:
“Practice-changing data from EMBER3 presented by Komal Jhaveri and concomitantly published on NEJM. Imlunestrant + abemaciclib likely to become soon a new 2L treatment option for HR+/HER2- MBC. Major question: should this option be for all-comers or only pts with ESR1mut tumors?”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
